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Heterogeneity of prodromal Parkinson symptoms in siblings of
Parkinson disease patients
Luca Baldelli1, Sebastian Schade 2,3, Silvia Jesús4,5, Sebastian R. Schreglmann6, Luisa Sambati1,7, Pilar Gómez-Garre 4,5,
Claire Halsband2,3, Giovanna Calandra-Buonaura1,7, Astrid Daniela Adarmes-Gómez4,5, Friederike Sixel-Döring8,9, Corrado Zenesini7,
Chiara Pirazzini7, Paolo Garagnani10, Maria Giulia Bacalini7, Kailash P. Bhatia6, Pietro Cortelli1,7, Brit Mollenhauer8,11, Claudio Franceschi7,
PROPAG-AGEING consortium*, Pablo Mir 4,5, Claudia Trenkwalder3,8 and Federica Provini 1,7✉
A prodromal phase of Parkinson’s disease (PD) may precede motor manifestations by decades. PD patients’ siblings are at higher
risk for PD, but the prevalence and distribution of prodromal symptoms are unknown. The study objectives were (1) to assess motor
and non-motor features estimating prodromal PD probability in PD siblings recruited within the European PROPAG-AGEING project;
(2) to compare motor and non-motor symptoms to the well-established DeNoPa cohort. 340 PD siblings from three sites (Bologna,
Seville, Kassel/Goettingen) underwent clinical and neurological evaluations of PD markers. The German part of the cohort was
compared with German de novo PD patients (dnPDs) and healthy controls (CTRs) from DeNoPa. Fifteen (4.4%) siblings presented
with subtle signs of motor impairment, with MDS-UPDRS-III scores not clinically different from CTRs. Symptoms of orthostatic
hypotension were present in 47 siblings (13.8%), no different to CTRs (p= 0.072). No differences were found for olfaction and
overall cognition; German-siblings performed worse than CTRs in visuospatial-executive and language tasks. 3/147 siblings had
video-polysomnography-confirmed REM sleep behavior disorder (RBD), none was positive on the RBD Screening Questionnaire.
173/300 siblings had <1% probability of having prodromal PD; 100 between 1 and 10%, 26 siblings between 10 and 80%, one
fulfilled the criteria for prodromal PD. According to the current analysis, we cannot confirm the increased risk of PD siblings for
prodromal PD. Siblings showed a heterogeneous distribution of prodromal PD markers and probability. Additional parameters,
including strong disease markers, should be investigated to verify if these results depend on validity and sensitivity of prodromal
PD criteria, or if siblings’ risk is not elevated.
npj Parkinson’s Disease            (2021) 7:78 ; https://doi.org/10.1038/s41531-021-00219-1
INTRODUCTION
Parkinson’s disease (PD) is the second most frequent neurode-
generative disease with a prevalence of 50–300 per 100,000 for all
ages, the incidence ranges from 10 to 30 per 100,000 person-years
in western countries1. Both prevalence and incidence increase
nearly exponentially with age and peak at 6% after the age of
802,3. Risk factors for PD neurodegeneration lie in the various and
complicated interplay between genetics and the environment,
both of which contribute to the intrinsic heterogeneous nature of
the disease4. The contribution of genetics to PD risk is currently
estimated at around 30%, explained by a few monogenic5, but
mainly polygenic mechanisms6. Age is the greatest non-familial
risk factor7.
A prodromal phase of PD, characterized by a variety of non-
motor symptoms (NMS), may precede the motor manifestation of
the disease by years or even decades. When rapid eye movement
sleep behavior disorder (RBD) occurs, the brainstem including
subcoeruleus and reticularis magnocellularis nuclei and the limbic
system are already affected. Olfactory dysfunction, cognitive
impairment, autonomic dysfunction, pain, or fatigue may be
already present at early stages8–10, and can precede PD motor
onset11–13 in the so-called PD prodromal phase14,15. NMS are
present in the elderly general population as well, but a
combination of two or more NMS increases the risk of developing
PD, especially if combined with subtle motor impairment16–18.
Apart from idiopathic RBD, which has been widely studied as a
specific marker for PD and alpha-synucleinopathies14, constipation
and hyposmia make up the highest risk (up to 3.4 and 5.2-fold,
respectively)14,19–22, though being non-specific and common in
the general elderly population23–25. Although these markers are
still not widely used in clinical practice and show a heterogeneous
presentation in prodromal patients, the high conversion rate from
the premotor or prodromal phase of the disease to PD provides a
unique opportunity to directly observe disease development26.
Applying the Movement Disorders Society criteria for prodromal
PD, which obtained a 98.8% specificity in a 10-year longitudinal
study17, prodromal PD prevalence has been estimated around
2.4% in the general elderly population27.
As mentioned above, family history is associated with an
increased risk of PD development28. A metanalysis on epide-
miological, referral, and registry-based studies showed a 2.9-fold
increased risk in first-degree relatives of PD patients and a
4.4-fold increased risk of PD development in PD siblings29–32.
Some studies have specifically evaluated prodromal markers in
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these individuals9,33,34. More recently, PD first-degree relatives
(siblings) were specifically found more likely to suffer from
anxiety, depression, and clinically diagnosed RBD than con-
trols33. However, data are limited and the exact prevalence of
prodromal PD signs and symptoms in PD siblings, and how they
progress, are currently unknown.
The present work aims to comprehensively assess motor and
NMS in PD siblings, to potentially define a high-risk group for
developing PD for future interventions. We, therefore, considered
a cross-sectional multi-center group of PD siblings (Sibs) recruited
within the framework of the European PROPAG-AGEING (PPG)
project. Within PPG, PD siblings, who have not been diagnosed
with a neurodegenerative disease and do not fulfill the definition
criteria of PD, are recruited in order to validate candidate clinical
and biological (genetic, epigenetic, transcriptional, metabolic,
lipid, and/or glycan) PD markers, as extensively described in
Pirazzini et al.35.
We aimed to describe the presence, distribution, and
combination of motor and NMS in PD siblings and estimate
their prodromal PD probability, and to compare the presented
motor and NMS to the well-established longitudinal DeNoPa
cohort36.
RESULTS
Demographic and general clinical data
A total of 340 siblings (n= 141; 41.5% males) were included in
the study from the three recruiting centers, their mean age was
62.13 ± 10.72; SAS siblings (Spanish Sibs) were the youngest
aged 57.77 ± 11.17 years (p < 0.001). Four Sibs had two siblings
affected with PD. Alcohol and coffee consumption were more
frequent among German Sibs (57.7% and 88.2%, respectively),
while Spanish Sibs had the highest per capita alcohol daily dose
(20.51 ± 20.92 g/day; p < 0.001). Regarding comorbidities,
hypothyroidism was more prevalent among German Sibs
(19.2%; p < 0.001).
In order to exclude national clusterization, we compared the
120 German siblings with 159 unrelated German de novo PD
patients (dnPDs) and 109 controls (CTRs), who showed a uniform
mean age (p= 0.875). In comparison to dnPDs and CTRs, more
German Sibs were men (46% vs 38.6%; p < 0.001), had higher
education, and were more active smokers (p < 0.001). DeNoPa PDs
presented with a higher BMI than German Sibs (p= 0.001). CTRs
presented with the highest prevalence of dyslipidemia and the
lowest of hyperuricemia (CTRs vs German Sibs: p < 0.001 and
0.048, respectively).
Demographic data and comorbidities are shown in Table 1;
consumptions and medications intake can be found in Supple-
mentary Table 1, blood test data in Supplementary Table 2.
Motor evaluation and impact on daily living
Sibs obtained a median motor score of 0 (0–2) on the MDS-UPDRS
part III. Fifteen (4.4%) Sibs presented with subtle signs of motor
impairment (MDS-UPDRS part III score without action and postural
tremor >6). German Sibs showed higher MDS-UPDRS III scores and
reported a higher impact of motor symptoms on activities of daily
living (MDS-UPDRS part II) than Italian and Spanish Sibs, even
when adjusted for confounders.
Compared to CTRs, German Sibs presented with increased
signs of motor impairment on the MDS-UPDRS part III (p < 0.001),
12 (10.0%) of them obtained a score greater than 6. German Sibs
also presented with increased MDS-UPDRS part II scores than
CTRs (p < 0.001).
Complete data on motor evaluation and motor impact on daily
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Symptoms of orthostatic hypotension (OH) were the most
frequent (47 Sibs; 13.8%), with a greater prevalence in German
Sibs (p= 0.006) compared to Italian and Spanish Sibs, followed by
constipation (40 Sibs; 11.8%). There was a tendency for more
sexual dysfunction and orthostatic hypotension among German
Sibs than CTRs (p= 0.058, p= 0.073, and p= 0.072, respectively).
Complete autonomic data are presented in Table 3.
Among Sibs, the mean Sniffin’ Sticks Screening score was 9.51 ±
2.04; 22 Sibs (6.5%) were under the 10th percentile according to
age and sex. Olfaction identification testing showed no difference
between German Sibs and CTRs; dnPDs presented the worst
performances (p < 0.001). Complete olfaction data are presented
in Table 3.
Eight Sibs (2.4%) presented with anxiety disorder, 36 with
depression (10.6%), there were no differences between the three
recruiting centers. DnPDs suffered more from depression with a
trend for a higher prevalence of anxiety disorders than German
Sibs (p= 0.04 and 0.061, respectively); they also used more
antidepressants (p= 0.001). Detailed results on affective-
behavioral evaluation can be found in Table 4.
Sibs obtained an adjusted MoCA mean score of 26.22 ± 3.36;
109 Sibs (32.2%) showed abnormal results (score < 26 points). The
prevalence of individuals with an abnormal MoCA score was
partially comparable among the centers, although the test score
was higher in German Sibs (27.04 ± 2.99) compared to ISNB- and
Spanish Sibs. German Sibs did not score differently from CTRs.
DnPDs were two-fold more cognitively impaired on the MoCA
(p= 0.036) and presented with lower scores when compared to
German Sibs. When cognitive domains were considered in detail,
German Sibs scored worse than CTRs in visuospatial/executive
[0.42 (CI 0.16–0.69) points, p= 0.002] and language [0.43 (CI
0.20–0.65) points, p < 0.001] tasks, without being different from
dnPDs, and performed better than both groups in abstraction and
short-term memory tasks. Specific data on cognition can be found
in Table 4.
Sibs scored a median of 2 (0–4) points on the MDS-UPDRS part I
and was significantly higher in German Sibs (p < 0.001). In
addition, German Sibs showed a lower non-motor burden than
dnPDs (p < 0.001), but higher than CTRs (p < 0.001). MDS-UPDRS
part I data are shown in Table 2.
Sleep evaluation
One-hundred and forty-seven Sibs (49 German Sibs and 98 Italian
Sibs) underwent vPSG. Mean sleep efficiency (SE) was 74.47 ±
18.48% and significantly higher in Italian Sibs (p < 0.001). Italian
Sibs also showed a higher proportion of N3 sleep (p < 0.001).
Three (2.1%) Sibs (2 German Sibs, 1 ISNB-Sib) had vPSG-confirmed
RBD. All three RBD positive Sibs were negative on the RBDSQ
(score < 5). According to the RBDSQ, 27 (8.0%) Sibs were positive
for probable (clinical) RBD (pRBD). Among the 27 pRBD, 18 Sibs
were investigated with a vPSG, which excluded RBD in each
of them.
vPSG-confirmed RBD was not more prevalent in German Sibs
than in CTRs (4.3% vs 1.8%, respectively), whilst it was more
frequent in dnPDs (25.3%).
RBD results are shown in Table 4, complete vPSG data can be
found in Supplementary Table 3.
Prodromal PD probability
Prodromal PD probability was calculated according to MDS
Research Criteria for Prodromal PD15, in their revised form20. The
300 Sibs over the age of 50 obtained a median prodromal PD
probability of 0.75% (0.32–2.19%). One hundred and seventy-three
Sibs had a <1% probability of having prodromal PD, 100 Sibs
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probability >10% (Fig. 1a). None of the 4 Sibs with two affected PD
siblings had a probability greater than 10%. One sibling (0.33%)
exceeded 80% probability (95.9%), fulfilling the criteria for
Prodomal PD: he presented vPSG-confirmed RBD, constipation,
and MDS-UPDRS III >6. The other two Sibs with confirmed RBD,
the greatest prodromal PD risk factor, presented a probability of
40.2% and 36.8%, respectively.
One hundred and twelve German Sibs and 107 CTRs from
DeNoPa over the age of 50 were evaluated for prodromal PD
probability; family history of PD was not taken into consideration
for this comparison. German Sibs presented with a median
prodromal PD probability of 0.43% (0.17–1.09%), statistically
greater than CTRs [0.215 (CI 0.12–0.45%), p < 0.001]. One UMG-
Sib and no CTRs fulfilled the criteria for prodromal PD. The
distribution of prodromal PD probability values was more
heterogeneous in the German Sibs group compared to CTRs
(Fig. 1b).
Detailed results on prodromal PD probability are shown in
Table 5.
Distribution of prodromal PD markers
One hundred and forty-six out of 340 Sibs (42.9%) presented at
least one prodromal PD marker, of whom 104 (30.6%) had only
one marker, 29 (8.5%) had 2 markers and 13 (3.8%) had 3 markers.
The most frequently associated markers were constipation and
depression in 11 Sibs, followed by symptoms of OH-constipation
and symptoms of OH-depression (7 Sibs each) (Supplementary
Fig. 1, Part A).
Fifty-nine out of 120 (49.2%) German Sibs and 40 out of 109
(36.7%) CTRs presented at least one prodromal PD marker.
The most frequently associated markers in German Sibs were
constipation and depression (6 siblings) (Supplementary Fig. 1,
Part B i), while in CTRs impaired olfaction and depression (3
controls) (Supplementary Fig. 1, Part B ii) were present. No
difference was present between German Sibs and CTRs in the
number of prodromal PD markers, when correcting for not equally
distributed variables (adjusted p= 0.388).
Results on prodromal PD markers distribution are shown in
Table 5.
DISCUSSION
To the best of our knowledge, this is the largest multi-national PD
siblings’ study and the first one extensively evaluating motor and
NMS and video-polysomnographically-validated RBD in this
population9,33,34. In our study, we used a multi-national recruit-
ment design with the inherent advantage of avoiding the gap of
specific population characteristics and preventing the limitation of
generalizability of the results. As part of our methodological
approach, we analyzed both the MDS estimate of prodromal
PD probability15,20 and considered the distribution of prodromal
PD markers.
The main findings of our study are the following:
1. PD siblings showed subtle signs of motor and non-motor
impairment, but when comparing German Sibs with CTRs,
the differences were either not significant or did not fulfill
criteria for clinical relevance, as outlined by Horvath37,38.
From the motor point of view, the siblings obtained motor
results comparable to non-converters, low-risk individuals16,
and the general elderly population39, also the prevalence of
siblings with mild parkinsonian signs was comparable to the
general population40.
2. Regarding NMS, no relevant differences were found among
Sibs from the three centers and between German Sibs and
CTRs. German Sibs showed a significant increase of NMS
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respect to CTRs, even if they differed by only 1 point. Our
data agree with one out of the only three studies evaluating
NMS in PD relatives, which did not find any difference with
healthy controls9. The other two studies found an increased
prevalence of anxiety and depression in PD relatives33,34.
These incongruences could be explained by the different
cohorts considered (first-degree relatives in general vs
siblings) and by the different methodologies used to assess
depression and anxiety (questionnaires and database
records vs medical history). Indeed, our results show that
reactive anxiety and depression, possibly related to the fear
of developing PD, is not an issue in our population.
3. The prevalence of participants with an abnormal MoCA
score was partially comparable among the centers. German
Sibs did not perform differently from CTRs according to
MoCA total score. However, German Sibs performed
significantly worse than CTRs in visuospatial-executive
functions and language, becoming similar to dnPDs in
these subtests. Occurrence and characteristics of cognitive
decline before PD onset are poorly understood41. To date,
just three prospective population studies18,42,43 have
demonstrated how lower scores in executive, visuospatial,
and language functions could increase the risk of develop-
ing PD, while one study found lower cognitive performances
to be connected with a higher probability of prodromal
PD44. Only one study considered cognition in PD relatives,
without evaluation of specific cognitive domains, finding no
differences with controls33.
4. PD siblings did not show a higher prevalence of vPSG-
validated RBD compared to the general population. Indeed,
of the 147 Sibs evaluated by vPSG, only 3 Sibs had
confirmed RBD. Using RBDSQ, Liu et al. previously reported
an RBD prevalence in PD Sibs of 13.3% against 3.6% in
controls33, which we were not able to confirm in our
cohorts. However, in our cohort, we did not find con-
cordance between vPSG and RBDSQ, and it is possible that
in previous studies the use of RBDSQ overestimated the
prevalence of RBD in PD sibs as the RBDSQ has not been
validated in the general population and its specificity is
generally low45–47.
5. Although the Sibs cohort is expected to be at higher risk29,
only one Sib out 300 met the criteria for probable prodromal
PD; this prevalence is not higher than the findings in a
population cohort of otherwise healthy elderly individuals27.
In our settings, the estimate of prodromal PD probability
fails to identify PD siblings as a cohort at high risk as a whole
and, therefore, the criteria of prodromal PD, which are
mainly driven by the presence of RBD, do not show a higher
risk of PD in our cohort. Whether this result depends on the
validity or better on the sensitivity of the prodromal PD
criteria or if the risk is actually not elevated in PD siblings
cannot reliably be answered by the current data.
6. PD siblings showed a heterogeneous distribution of
prodromal PD probability when using the MDS criteria for
prodromal PD, as highlighted by the comparison between
German Sibs and German CTRs. Twenty-seven of 300 Sibs
had a probability of more than 10% of having prodromal PD
and 42 of 340 Sibs presented at least two PD markers,
hence, at-risk subjects were few but highly impacted48. In
fact, by evaluating the distribution of score values and
combined markers a subgroup of higher-risk individuals
emerged, which disappears, if the specific marker of RBD is
added and calculated.
Collectively, these results suggest on one hand that a
reappraisal of currently available tools is needed, as they are only
in part able to grasp the higher risk of PD siblings as reported by
epidemiological data. Strong markers from additional clinical,
biochemical (such as abnormal synuclein in the cerebrospinal fluid
or in tissues), and molecular (e.g., polymorphisms in known at-risk
loci) parameters should be investigated to increase their sensi-
tiveness and help in disentangling heterogeneity as an intrinsic
feature of PD neurodegeneration process. In parallel with PD
subtypes, heterogeneity can reside also in the prodromal state
and without broadening our search we could miss many
prodromal PD patients. On the other hand, our results did show
that prodromal symptoms are very uncommon in siblings, which
could suggest that the low sibling risk is not a question of partial
penetrance, but that siblings despite being more epidemiologi-
cally at risk of developing PD would not stall at a prodromal stage
before some of them actually manifested the disease. Indeed,
recent evidence showed borderline sensitivity when applying
prodromal PD to the incident or longitudinal not enriched
cohorts49,50.
Our study has several limitations. First, data of a de novo PD
cohort were only available for the German center and we,
therefore, decided to compare only German Sibs with de novo PD
and controls, thus reducing numbers and statistical power.
Second, genetic tests for known PD variants were not carried
out at this stage. Third, apart from sleep with vPSG and odor
identification impairment, other NMS were evaluated using
patient reports and questionnaires, without instrumental or
objective measurements, especially for strong prodromal NMS
such as orthostatic hypotension. No interrater testing or training
was performed prior to the study in the three sites, therefore
interrater variabilities could account for the differences in ratings.
The sleep studies are only partially comparable, as there are
inherent differences between the compared lab-based vPSG in
Fig. 1 Prodromal PD probability of Siblings and DeNoPa cohorts.
a Density distribution of prodromal PD probability. b Density
distribution of prodromal PD probability in German Sibs and CTRs.
L. Baldelli et al.
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Germany (UMG) and the home-based vPSG (ISNB), although both
centers are experienced in PSG RBD diagnosis, while no vPSGs
data were included from SAS.
On the other hand, our study described motor and non-motor
clinical and video-polysomnographic features in the largest PD
sibling cohort up to date, using a multi-center approach, thus
excluding the risk of clustered genetic and environmental risk
factors related to the geographical context, especially in enclosed
communities30. Furthermore, PD patients and siblings were not
related but originated from different families. Indeed, the previous
studies9,33,34 showed strong similarities between PD patients and
siblings due to familial clustering, affecting not only PD-related
markers but also possibly biasing features.
Our study indicates that siblings have a heterogeneous
distribution of motor and non-motor signs. Additional clinical,
biochemical, and molecular parameters not currently included in
MDS criteria, and a focalized analysis of the more at-risk subjects,
should pave the way of future analyses within the project. Finally,
a prospective follow-up of an expanded collaborative international
cohort can represent the right path to disentangle the complex
interplay between genetic and environmental factors, characteriz-




We report the description of the PPG siblings cohort (Sibs) multicentrically
recruited over 29 months between September 2016 and January 2019 by
three PPG partners: Azienda Unità Sanitaria Locale di Bologna—IRCCS
Istituto delle Scienze Neurologiche di Bologna (ISNB, Italy), Servicio
Andaluz de Salud (SAS, Spain) and Paracelsus-Elena Hospital, Kassel as
part of Universitätsmedizin Göttingen (UMG-GOE, Germany). Sibs from
Bologna and Kassel underwent video-polysomnography. To account for
population-specific effects we subsequently compared sibling data from
UMG-GOE (German-Sibs) with the baseline data of de novo PD patients
(dnPDs) and controls (CTRs) from the DeNoPa cohort from the same
center36 (Fig. 2).
Study participants
Siblings of patients with a diagnosis of idiopathic PD according to the
International Diagnostic Criteria (UK Brain Bank Criteria51), were recruited.
The diagnoses of the affected PD patients were verified in each recruiting
center by neurologists experienced in movement disorders, all belonging
to the PROPAG-AGEING Consortium. Participants had to be over 18 years
of age and could not have any active known/treated condition of the
central nervous system (e.g., Alzheimer’s disease, vascular encephalopa-
thies, multiple sclerosis) including PD; data on dnPDs and CTRs were
retrieved from DeNoPa database36. DeNoPa is a large single-center cohort
of early PD patients recruited at Paracelsus-Elena Hospital, Kassel including
frequency-matched healthy controls. DeNoPa’s subjects evaluation
includes motor signs, NMS, and a combination of diagnostic tests
including olfactory testing, transcranial sonography of substantia nigra,
and polysomnography (PSG)36.
Investigations
Each recruited sibling received a full clinical evaluation including complete
medical history, accounting for both comorbidities and medication, and a
neurological examination performed by a neurologist experienced in
movement disorder assessment. Motor symptoms were quantitatively
assessed using the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
part III, while the impact on activities of daily living and NMS was assessed
by the MDS-UPDRS parts II and I52. NMS were evaluated by means of
validated questionnaires, such as the Non-Motor Symptoms Questionnaire
(NMSQ—questions 26 and 30)53, the Rome III Diagnostic Criteria for
Functional Constipation54,55, the Montreal Cognitive Assessment (MoCA)56
and the REM sleep behavior disorder screening questionnaire (RBDSQ)46.
We also objectively assessed olfactory function using Sniffin’ Sticks
Screening57, obtained selected laboratory and blood parameters (ISNB
and UMG-GOE only), and carried out a whole night video-
polysomnography (vPSG) in ISNB (at home) and UMG-GOE (in the sleep
laboratory) recruited siblings. ISNB home-based vPSG was performed by
means of Xltek Trex HD Video Ambulatory system and included three
monopolar electroencephalogram channels (as recommended by the
American Academy of Sleep Medicine’s Manual for the Scoring of Sleep
and Associated Events58), electrocardiogram (EKG), electrooculogram
(EOG), chin and limbs EMG (bilateral extensor carpi and tibialis anterior
muscles), and toraco-abdominal respirogram. UMG-GOE lab-based vPSG
was performed applying cardiorespiratory PSG and including bilateral
monopolar central EEG with 2 channels, EOG, chin and bilateral tibialis
anterior surface EMG, airflow registration, tracheal sound registration by
microphone, thoracic and abdominal belts to measure respiratory move-
ments, EKG, and oximetry. All patients were documented with an infrared
video recording synchronized to the PSG. Further methodological details
are described as published elsewhere59.
Table 5. Prodromal PD Probability and Markers in siblings and DeNoPa cohorts.
PROPAG-AGEING Siblings’ cohort DeNoPa cohort Comparisons with DeNoPa
Total Sibs Italian Sibs Spanish Sibs German Sibs CTRs CTRs vs German Sibs
n= 300 n= 92 n= 96 n= 112 n= 107 IRR (CI)/βcoef. (CI) Adj. p
Prodromal PD calculation
Prodromal PD probability (%) 0.75 (0.32–2.19) 0.54 (0.27–1.27) 0.80 (0.28–2.32) 1.07 (0.43–2.69) – – –
Log10(probability) −0.04 ± 0.66 −0.20 ± 0.62 −0.06 ± 0.62 0.10 ± 0.70 – – –
Prodromal PD probability
without fam. his. (%)
0.30 (0.13–0.91) 0.22 (0.11–0.57) 0.32 (0.11–0.94) 0.43 (0.17–1.09) 0.21 (0.12–0.45) 0.64 (0.51–0.82) <0.001
Log10(probability) −0.40 ± 0.86 −0.49 ± 1.16 −0.45 ± 0.64 −0.28 ± 0.73 −0.58 ± 0.63 −0.22 (−0.41–−0.03) 0.025
Prodromal PD positive 1 (0.33%) 0 (0.0%) 0 (0.0%) 1 (0.9%) 0 (0.0%) – –
Prodromal PD markers n= 340 n= 100 n= 120 n= 120 n= 109 OR (CI) p
# of markers 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1) 0.75 (0.39–1.43) 0.388
≥2 markers 42 (12.3%) 8 (8%) 14 (11.7%) 20 (16.7%) 11 (10.1%) 0.53 (0.18–1.55) 0.247
Continuous, not normally distributed variables and ordinal variables are expressed in median (1st–3rd quartile), continuous, normally distributed variables are
expressed in mean ± standard deviation, discrete in number (%). Adjustments have been made for age, sex, education, smoking, and coffee intake. Statistically
significant coefficients and p-values are reported in bold.
Group acronyms are the same as explained in Table 1; Adj. p p-adjusted for covariates, IRR incidence rate ratio, CI 95% confidence interval, βcoef. coefficient of
regression from linear regression, Prodromal PD probability without fam. his. prodromal PD probability computed without considering the history of PD in first-
degree relatives, Log10(probability) base 10 logarithm of prodromal PD probability.
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Computation of prodromal PD probability and evaluation of
prodromal PD markers
Prodromal PD probability for Sibs over the age of 50 was computed
according to the revised MDS Research Criteria20, which also outlined
the prodromal PD markers considered for evaluation. Life risk and
prodromal markers were evaluated and accounted for each participant,
independently of their age. Subsequent prodromal PD probability
calculation taking into account prior probability was computed for
those over the age of 50 (prior probability estimates are not available in
the literature for younger individuals). Risk scoring was computed as
defined in refs. 15,20.
Risk markers were evaluated as follows:
● Sex: biological sex was considered for the purpose. No cases of
hermaphroditism or pseudohermaphroditism were present in our
cohorts.
● Pesticide and solvent exposure: data not systematically available (NsA)
in our cohort and therefore not computed.
● Non-use of caffeine: evaluated as defined in refs. 15,20.
● Smoking: evaluated as defined in refs. 15,20.
● First-degree relative with PD: this risk marker, positive for every sibling
in our cohort, was evaluated in the first computation of prodromal PD
probability, while it was not taken into account in the comparison
between German siblings and healthy controls, to exclude obvious
biasing in the calculation. Known gene mutation and polygenic risk
scores were not taken into account.
● Substantia nigra hyperechogenicity: NsA data.
● Diabetes mellitus type II: retrieved from accurate medical history.
● Physical inactivity: NsA data.
● Low plasma urate in men: evaluated as defined in ref. 20.
Prodromal markers were evaluated as follows:
● REM sleep behavior disorder (RBD): evaluated as defined in refs. 15,20.
However, when the prodromal markers were evaluated for their
distribution rather than for the calculation of prodromal PD
probability, only video-polysomnographically validated RBD was
considered as positive RBD, to guarantee a homogeneous methodo-
logical approach.
● Nuclear medicine dopaminergic imaging: NsA data.
● Subthreshold parkinsonism: MDS-UPDRS-III >6 excluding postural and
action tremor evaluation was considered.
● Olfactory loss: available sex and age correction, provided by the
manufacturer, for olfactory identification testing was adopted. In order
to maintain a conservative approach (to prevent overestimation of
prodromal markers), only individuals under the 10th percentile
according to age and sex were considered as having an objective
olfactory dysfunction.
● Constipation: individuals fulfilling Rome III Diagnostic Criteria for
Functional Constipation (thus excluding primarily gastrointestinal
causes) were considered positive for this marker54,55.
● Excessive daytime somnolence: individuals with a score ≥3 on MDS-
UPDRS question 1.8, thus responding positively to the following
statement: “I sometimes fall asleep when I should not. For example,
while eating or talking with other people.”
● Neurogenic orthostatic hypotension (OH): NsA data.
● Symptomatic OH: symptoms of OH were evaluated using a semi-
structured clinical interview based on either Non-Motor Symptoms
Questionnaire or MDS-UPDRS question 1.12.
● Erectile dysfunction in men: erectile dysfunction in men was evaluated
using a semi-structured clinical interview based on Non-Motor
Symptoms Questionnaire.
● Urinary dysfunction: individuals with a score ≥3 at MDS-UPDRS
question 1.10, thus responding positively to the following statement:
“Urine (control) problems cause a lot of difficulties with my daily
activities, including urine accidents.”
● Depression (±anxiety): individuals were considered positive for
depression (and/or anxiety) only when actual disorders, requiring
pharmacological treatment and/or psychological assistance, were
reported during the clinical interview.
● Global cognitive deficit: cognition was evaluated using the Montreal
Cognitive Assessment (MoCA) in our cohort, which presented several
issues of cutoff identification when individuals from different
nationalities needed to be compared. Therefore, in order to maintain
a conservative approach, MoCA score distribution was computed for
each subgroup and nationality, individuals below 2 standard devia-
tions were selected as cognitively impaired for prodromal marker
selection. It should be noted that our approach is more conservative
than the original methodology used by Heinzel et al. to compute the
Global cognitive deficit risk score of 1.8, which was derived from
studies using a cutoff of only 1 standard deviation20.
Standard protocol approvals, registrations, and patient
consents
We conducted the study according to the Declaration of Helsinki and all
participants provided informed written consent. The study was approved
by the local ethics committees of each recruiting PPG partner (UMG-GOE
ethics committee no. of approval 19/5/16 of August 2016, ISNB ethics
committee no. of approval 16018 of May 2016, SAS ethical committee no.
of approval 2014/PI173 of September 2016).
Database and statistical analysis
A designated online database was created for the study and collected
demographic and laboratory data, clinically relevant comorbidities, and
questionnaire results. All continuous normally distributed data were
expressed as means and standard deviations (SD), while not normally
distributed data were expressed as medians and interquartile ranges (IQR);
the categorical data were expressed as absolute frequency and
percentages (%).
Chi-squared, one-way analysis of variance (ANOVA) or Kruskal-Wallis test
were used to investigate the differences between groups (German Sibs
and DeNoPa’s dnPDs and CTRs) and PD siblings grouped by enrollment
center (UMG-GOE, ISNB, SAS) and the demographic and lifestyle variables,
comorbidities, medications, MDS-UPDRS parameters, NMS, blood tests, and
macrostructure sleep data.
Multivariate logistic regression models, multivariate linear regression
models, and multivariate Poisson regression models were used to evaluate
Fig. 2 Study tree of the compared cohorts. Siblings were multicentrically recruited in Italy, Spain and Germany, German siblings were then
compared with de novo PD patients and controls from the DeNoPa German cohort.
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the differences between groups and variables described above, adjusted
for the following confounding variables of age, sex, years of education,
smoking (cigarettes per day), and coffee intake (cups per day). The results
were presented as odds ratios (OR) (95% confidence interval—CI) or β
coefficient (95% CI) or incidence rate ratio (IRR) (95% CI).
Statistical analysis was performed using SPSS Statistics version 21 (IBM,
Armonk, NY, USA) and Stata SE version 14.2 (StataCorp LLC, Texas, USA).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
Anonymized data and metadata will be shared by request from any qualified
investigator.
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